Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial - Concepedia

Concepedia

Publication | Open Access

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

DOI Full Paper Access

103

Citations

17

References

2017

Year

Christopher Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang, David Bottomley, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan, Sophie D. Fosså, Aleš Chodacki,

European Urology

References

	Year	Citations

Page 1